Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02571777
Other study ID # CQVM149B2302
Secondary ID 2015-002899-25
Status Completed
Phase Phase 3
First received
Last updated
Start date December 8, 2015
Est. completion date June 14, 2019

Study information

Verified date July 2020
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320) μg via Concept1 in poorly controlled asthmatics as determined by pulmonary function testing and effects on asthma control.


Description:

This study used a 52-week treatment, randomized, double-blind, double-dummy, parallel-group design. A total of 3092 asthma patients were randomized into the 5 treatment groups with a randomization ratio of 1:1:1:1:1 (approximately 617 patients per treatment group): QVM149 150/50/80 μg once daily (o.d.), QVM149 150/50/160 μg o.d., QMF149 150/160 μg o.d. and QMF149 150/320 μg o.d., all delivered via the Concept1 device, and salmeterol/fluticasone 50/500 μg twice daily (b.i.d.) delivered via Accuhaler. The 52 week treatment period was followed by a 30-day Follow-up.

The primary objective of this study was to demonstrate superiority of either QVM149 150/50/80 μg o.d. to QMF149 150/160 μg o.d. or QVM149 150/50/160 μg o.d. to QMF149 150/320 μg o.d in terms of trough Forced Expiratory Volume in One Second (Trough FEV1) (FEV1) at Week 26, all delivered via Concept1.


Recruitment information / eligibility

Status Completed
Enrollment 3092
Est. completion date June 14, 2019
Est. primary completion date June 14, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients with a diagnosis of asthma, (GINA 2015) for a period of at least 1 year prior to Visit 1 (Screening).

- Patients who have used medium or high dose of ICS/LABA combinations for asthma for at least 3 months and at stable medium or high doses of ICS/LABA for at least 1 month prior to Visit 1.

- Patients must be symptomatic at screening despite treatment with mid or high stable doses of ICS/LABA. Patients with ACQ-7 score = 1.5 at Visit 101 and at Visit 102 (before randomization).

- Patients with documented history of at least one asthma exacerbation which required medical care from a physician, ER visit (or local equivalent structure) or hospitalization in the 12 months prior to Visit 1, and required systemic corticosteroid treatment.

- Pre-bronchodilator FEV1 of < 80 % of the predicted normal value for the patient according to ATS/ERS guidelines after withholding bronchodilators at both visits 101 and 102.

- Withholding period of bronchodilators prior to spirometry: SABA for = 6 hrs, Twice daily LABA (or FDC of ICS/LABA) for = 12 hrs, Once daily LABA (or FDC of ICS/LABA) for = 24 hrs, SAMA for = 8 hrs, Short acting xanthines for 12 hrs, Long acting xanthines for 24 hrs, .

- Washout period of each drug should be kept as close as possible as above and should not be longer. If longer washout period is needed due to scheduling issues, please contact Novartis Medical monitor.

- A one-time repeat of percentage predicated FEV1 (Pre-bronchodilator) at Visit 101 and/or Visit 102 is allowed in an ad-hoc visit. Repeat of Visit 101 spirometry should be done in an ad-hoc visit to be scheduled on a date that would provide sufficient time to receive confirmation from the spirometry data central reviewer of the validity of the assessment before randomization. Run-in medication should be dispensed once spirometry assessment met inclusion criteria (ATS/ERS quality criteria, FEV1 % predicted normal value, and reversibility) as per equipment

- A one-time rescreen is allowed in case the patient fails to meet the criteria at the repeat, provided the patient returned to the required treatment as per inclusion criteria 4

- Patients who demonstrate an increase in FEV1 of 12% and 200 mL within 30 minutes after administration of 400 µg salbutamol/360 µg albuterol (or equivalent dose) at Visit 101.All patients must perform a reversibility test at Visit 101. If reversibility is not demonstrated at Visit 101 then one of the following criteria need to be met.

- Reversibility should be repeated once.

- Patients may be permitted to enter the study with historical evidence of reversibility that was performed according to ATS/ERS guidelines within 2 years prior to Visit 1.

- Alternatively, patients may be permitted to enter the study with a historical positive bronchoprovocation test that was performed within 2 years prior to Visit 1. If reversibility is not demonstrated at Visit 101 (or after repeated assessment in an ad-hoc visit) and historical evidence of reversibility/bronchoprovocation is not available (or was not performed according to the ATS/ERS guidelines patients must be screen failed

- Spacer devices are permitted during reversibility testing only. The Investigator or delegate may decide whether or not to use a spacer for the reversibility testing

Exclusion Criteria:

- Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening). If patients experience an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit between Visit 1 and Visit 102 they may be re-screened 6 weeks after recovery from the exacerbation.

- Patients who have ever required intubation for a severe asthma attack/exacerbation.

- Patients who have a clinical condition which is likely to be worsened by ICS administration (e.g. glaucoma, cataract and fragility fractures) who are according to investigator's medical judgment at risk participating in the study.

- Patients treated with a LAMA for asthma within 3 months prior Visit 1 (Screening).

- Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or bladder-neck obstruction or severe renal impairment or urinary retention. BPH patients who are stable on treatment can be considered).

- Patients who have had a respiratory tract infection or asthma worsening as determined by investigator within 4 weeks prior to Visit 1 (Screening) or between Visit 1 and Visit 102. Patients may be re-screened 4 weeks after recovery from their respiratory tract infection or asthma worsening.

- Patients with evidence upon visual inspection (laboratory culture is not required) of clinically significant (in the opinion of investigator) oropharyngeal candidiasis at Visit 102 or earlier, with or without treatment. Patients may be re-screened once their candidiasis has been treated and has resolved.

- Patients with any chronic conditions affecting the upper respiratory tract (e.g. chronic sinusitis) which in the opinion of the investigator may interfere with the study evaluation or optimal participation in the study.

- Patients with a history of chronic lung diseases other than asthma, including (but not limited to) chronic obstructive pulmonary disease, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.

- Patients with Type I diabetes or uncontrolled Type II diabetes.

- Patients who, either in the judgment of the investigator or the responsible Novartis personnel, have a clinically significant condition such as (but not limited to) unstable ischemic heart disease, New York Heart Association (NYHA) Class III/IV left ventricular failure arrhythmia, uncontrolled hypertension, cerebrovascular disease, psychiatric disease, neurodegenerative diseases, or other neurological disease, uncontrolled hypo- and hyperthyroidism and other autoimmune diseases, hypokalemia, hyperadrenergic state, or ophthalmologic disorder or patients with a medical condition that might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study.

- Patients with paroxysmal (e.g., intermittent) atrial fibrillation are excluded. Patients with persistent atrial fibrillation as defined by continuous atrial fibrillation for at least 6 months and controlled with a rate control strategy (i.e., selective beta blockers, calcium channel blocker, pacemaker placement, digoxin or ablation therapy) for at least 6 months may be considered for inclusion. In such patients, atrial fibrillation must be present at the run-in visit (Visit 101) with a resting ventricular rate < 100/min. At Visit 101 the atrial fibrillation must be confirmed by central reading.

- Patients with a history of myocardial infarction (this should be confirmed clinically by the investigator) within the previous 12 months.

- Concomitant use of agents known to prolong the QT interval unless it can be permanently discontinued for the duration of study

- Patients with a history of long QT syndrome or whose QTc measured at Visit 101 (Fridericia method) is prolonged (> 450 msec for males and > 460 msec for females) and confirmed by a central assessor (these patients should not be rescreened).

- Patients with a history of hypersensitivity to lactose, any of the study drugs or to similar drugs within the class including untoward reactions to sympathomimetic amines or inhaled medication or any component thereof.

- Patients who have not achieved an acceptable spirometry result at Visit 101 in accordance with ATS/ERS criteria for acceptability and repeatability. A one-time repeat spirometry is allowed in an ad-hoc visit scheduled as close as possible from the first attempt (but not on the same day) if the spirometry did not qualify due to ATS/ERS criteria at Visit 101 and/or Visit 102. If the patient fails the repeat assessment, the patient may be rescreened once, provided the patient returns to the required treatment as per inclusion criteria 4.

- Patients unable to use the Concept1 dry powder inhaler, Accuhaler or a metered dose inhaler. Spacer devices are not permitted.

- History of alcohol or other substance abuse.

- Patients with a known history of non-compliance to medication or who were unable or unwilling to complete a patient diary or who are unable or unwilling to use Electronic Peak Flow with e-diary device.

- Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
QVM149 150/50/160

QVM149 150/50/80

QMF149 150/320

QMF149 150/160

salmeterol/fluticasone


Locations

Country Name City State
Argentina Novartis Investigative Site Bahia Blanca Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Concepcion del Uruguay Entre Rios
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Florida Buenos Aires
Argentina Novartis Investigative Site Godoy Cruz Mendoza
Argentina Novartis Investigative Site Lanus Buenos Aires
Argentina Novartis Investigative Site Mar del Plata Buenos Aires
Argentina Novartis Investigative Site Mar del Plata Buenos Aires
Argentina Novartis Investigative Site Mendoza
Argentina Novartis Investigative Site Mendoza
Argentina Novartis Investigative Site Nueve de Julio Buenos Aires
Argentina Novartis Investigative Site Parana
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site San Miguel de Tucuman Tucuman
Argentina Novartis Investigative Site San Nicolas Buenos Aires
Argentina Novartis Investigative Site Santa Fe
Argentina Novartis Investigative Site Santa Fe
Argentina Novartis Investigative Site Santa Fe Rosario
Argentina Novartis Investigative Site Vicente Lopez Buenos Aires
Argentina Novartis Investigative Site Villa Maria Cordoba
Austria Novartis Investigative Site Bludenz
Austria Novartis Investigative Site Feldbach
Austria Novartis Investigative Site Feldkirch
Austria Novartis Investigative Site Grieskirchen
Belgium Novartis Investigative Site Braine L Alleud Waterloo
Belgium Novartis Investigative Site Bruxelles
Belgium Novartis Investigative Site Bruxelles
Belgium Novartis Investigative Site Eghezee
Belgium Novartis Investigative Site Erpent
Belgium Novartis Investigative Site Gosselies BEL
Belgium Novartis Investigative Site Hasselt BEL
Belgium Novartis Investigative Site Jette Brussel
Belgium Novartis Investigative Site Lebbeke
Belgium Novartis Investigative Site Liege
Belgium Novartis Investigative Site Malmedy
Bulgaria Novartis Investigative Site Plovdiv BGR
Bulgaria Novartis Investigative Site Ruse
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Stara Zagora
Canada Novartis Investigative Site Burlington Ontario
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Quebec
Canada Novartis Investigative Site Sherbrooke Quebec
Canada Novartis Investigative Site Sherwood Park Alberta
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Trois Rivieres Quebec
Canada Novartis Investigative Site Victoriaville Quebec
Canada Novartis Investigative Site Windsor Ontario
Canada Novartis Investigative Site Windsor Ontario
Chile Novartis Investigative Site Curico VII Region Del Maule
Chile Novartis Investigative Site Santiago
Chile Novartis Investigative Site Santiago
Chile Novartis Investigative Site Santiago Region Metropolitana
Chile Novartis Investigative Site Valparaiso TX
China Novartis Investigative Site Chang Chun Jilin
China Novartis Investigative Site Chengdu Sichuan
China Novartis Investigative Site Chongqing
China Novartis Investigative Site Haikou Hainan
China Novartis Investigative Site Nanjing Jiangsu
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shanghai Shanghai
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Suzhou Jiangsu
China Novartis Investigative Site Tianjin
China Novartis Investigative Site Xian Shanxi
Colombia Novartis Investigative Site Bogota
Colombia Novartis Investigative Site Bogota DC
Colombia Novartis Investigative Site Floridablanca
Colombia Novartis Investigative Site Medellin
Croatia Novartis Investigative Site Petrinja
Croatia Novartis Investigative Site Zadar
Croatia Novartis Investigative Site Zagreb
Croatia Novartis Investigative Site Zagreb HRV
Denmark Novartis Investigative Site Copenhagen NV
Denmark Novartis Investigative Site Hvidovre
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tartu
Finland Novartis Investigative Site Jyvaskyla
France Novartis Investigative Site Montpellier cedex 5 Herault
Germany Novartis Investigative Site Annaberg-Buchholz
Germany Novartis Investigative Site Aschaffenburg
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Bochum Nordrhein Westfalen
Germany Novartis Investigative Site Bonn
Germany Novartis Investigative Site Cottbus Sachsen
Germany Novartis Investigative Site Darmstadt
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Frankfurt am Main
Germany Novartis Investigative Site Geesthacht Schleswig Holstein
Germany Novartis Investigative Site Halle
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hannover
Germany Novartis Investigative Site Karlsruhe
Germany Novartis Investigative Site Koblenz NRW
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Lübeck
Germany Novartis Investigative Site Mainz
Germany Novartis Investigative Site Mittweida
Germany Novartis Investigative Site Neu Isenburg
Germany Novartis Investigative Site Potsdam
Germany Novartis Investigative Site Rudersdorf
Germany Novartis Investigative Site Witten
Greece Novartis Investigative Site Athens GR
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Heraklion Crete
Greece Novartis Investigative Site Thessaloniki GR
Greece Novartis Investigative Site Thessaloniki GR
Greece Novartis Investigative Site Thessaloniki GR
Hungary Novartis Investigative Site Balassagyarmat
Hungary Novartis Investigative Site Budaors HUN
Hungary Novartis Investigative Site Budapest HUN
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Eger HUN
Hungary Novartis Investigative Site Godollo
Hungary Novartis Investigative Site Kapuvár HUN
Hungary Novartis Investigative Site Komarom
Hungary Novartis Investigative Site Mateszalka
Hungary Novartis Investigative Site Nyiregyhaza
Hungary Novartis Investigative Site Puspokladany HUN
Hungary Novartis Investigative Site Szarvas
Hungary Novartis Investigative Site Szeged
Hungary Novartis Investigative Site Szeged
Hungary Novartis Investigative Site Szigetszentmiklos
Hungary Novartis Investigative Site Szigetvar
Hungary Novartis Investigative Site Tata HUN
India Novartis Investigative Site Ahmedabad Gujarat
India Novartis Investigative Site Ahmedabad Gujarat
India Novartis Investigative Site Bangalore Karnataka
India Novartis Investigative Site Bikaner Rajasthan
India Novartis Investigative Site Cherthala Kerala
India Novartis Investigative Site Coimbatore Tamil Nadu
India Novartis Investigative Site Dehli Delhi
India Novartis Investigative Site DehraDun Uttarakhand
India Novartis Investigative Site Guntur Andhra Pradesh
India Novartis Investigative Site Gurgaon Haryana
India Novartis Investigative Site Hubli Karnataka
India Novartis Investigative Site Hyderabad Telangana
India Novartis Investigative Site Hyderabad Telangana
India Novartis Investigative Site Hyderabad Andhra Pradesh
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Kanpur Uttar Pradesh
India Novartis Investigative Site Kochi Kerala
India Novartis Investigative Site Kolkata West Bengal
India Novartis Investigative Site Kozhikode Kerala
India Novartis Investigative Site Mangalore Karnataka
India Novartis Investigative Site Mohali Punjab
India Novartis Investigative Site Mumbai Maharashtra
India Novartis Investigative Site Mysore Karnataka
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nashik Maharastra
India Novartis Investigative Site New Delhi Delhi
India Novartis Investigative Site Patna Bihar
India Novartis Investigative Site Pune Maharashtra
India Novartis Investigative Site Pune Maharashtra
India Novartis Investigative Site Vellore Tamil Nadu
India Novartis Investigative Site Vijayawada Andhra Pradesh
India Novartis Investigative Site Vishakhapatnam Andhra Pradesh
Ireland Novartis Investigative Site Dublin
Ireland Novartis Investigative Site Wilton Cork
Israel Novartis Investigative Site Ashkelon
Israel Novartis Investigative Site Beer-Sheva
Israel Novartis Investigative Site Jerusalem
Israel Novartis Investigative Site Jerusalem
Israel Novartis Investigative Site Kfar Saba
Israel Novartis Investigative Site Petach Tikva
Israel Novartis Investigative Site Rehovot
Israel Novartis Investigative Site Tel Giborim, Holon
Italy Novartis Investigative Site Ancona
Italy Novartis Investigative Site Bari BA
Italy Novartis Investigative Site Catania CT
Italy Novartis Investigative Site Catanzaro CZ
Italy Novartis Investigative Site Firenze FI
Italy Novartis Investigative Site Messina ME
Italy Novartis Investigative Site Messina
Italy Novartis Investigative Site Negrar VR
Italy Novartis Investigative Site Pordenone
Italy Novartis Investigative Site Roma
Japan Novartis Investigative Site Chuo ku Tokyo
Japan Novartis Investigative Site Hamamatsu-city Shizuoka
Japan Novartis Investigative Site Himeji-city Hyogo
Japan Novartis Investigative Site Itabashi-ku Tokyo
Japan Novartis Investigative Site Kasuga-city Fukuoka
Japan Novartis Investigative Site Kawasaki-city Kanagawa
Japan Novartis Investigative Site Kishiwada-city Osaka
Japan Novartis Investigative Site Kokubunji-city Tokyo
Japan Novartis Investigative Site Kurashiki-city Okayama
Japan Novartis Investigative Site Naka-gun Ibaraki
Japan Novartis Investigative Site Obihiro-city Hokkaido
Japan Novartis Investigative Site Okayama-city Okayama
Japan Novartis Investigative Site Ota-ku Tokyo
Japan Novartis Investigative Site Sendai-city Miyagi
Japan Novartis Investigative Site Shinagawa-ku Tokyo
Japan Novartis Investigative Site Tokyo Shibuya Ku
Japan Novartis Investigative Site Tomakomai-city Hokkaido
Japan Novartis Investigative Site Toshima ku Tokyo
Japan Novartis Investigative Site Yokkaichi-city Mie
Japan Novartis Investigative Site Yokohama Kanagawa
Japan Novartis Investigative Site Yokohama-city Kanagawa
Japan Novartis Investigative Site Yokohama-city Kanagawa
Japan Novartis Investigative Site Yokohama-city Kanagawa
Jordan Novartis Investigative Site Amman JOR
Jordan Novartis Investigative Site Amman JOR
Latvia Novartis Investigative Site Balvi LVA
Latvia Novartis Investigative Site Bauska LVA
Latvia Novartis Investigative Site Daugavpils LVA
Latvia Novartis Investigative Site Daugavpils
Latvia Novartis Investigative Site Jurmala LVA
Latvia Novartis Investigative Site Rezekne LVA
Latvia Novartis Investigative Site Riga LVA
Latvia Novartis Investigative Site Riga LV
Latvia Novartis Investigative Site Riga LV
Latvia Novartis Investigative Site Riga
Lebanon Novartis Investigative Site Ashrafieh
Lebanon Novartis Investigative Site Beirut
Lebanon Novartis Investigative Site Beirut
Lebanon Novartis Investigative Site El Chouf LBN
Lithuania Novartis Investigative Site Kaunas
Lithuania Novartis Investigative Site Kaunas
Lithuania Novartis Investigative Site Kaunas
Lithuania Novartis Investigative Site Kaunas
Lithuania Novartis Investigative Site Kaunas LT
Lithuania Novartis Investigative Site Klaipeda
Lithuania Novartis Investigative Site Klaipeda
Lithuania Novartis Investigative Site Siauliai
Lithuania Novartis Investigative Site Vilnius
Lithuania Novartis Investigative Site Vilnius LT
Lithuania Novartis Investigative Site Vilnius LTU
Mexico Novartis Investigative Site Culiacan MEX
Mexico Novartis Investigative Site Guadalajara Jalisco
Mexico Novartis Investigative Site Guadalajara Jalisco
Mexico Novartis Investigative Site Guadalajara Jalisco
Mexico Novartis Investigative Site Guadalajara Jalisco
Mexico Novartis Investigative Site Monterrey Nuevo Leon
Mexico Novartis Investigative Site Oaxaca
Mexico Novartis Investigative Site Veracruz
Mexico Novartis Investigative Site Zapopan Jalisco
Netherlands Novartis Investigative Site Breda CK
Netherlands Novartis Investigative Site Eindhoven
Netherlands Novartis Investigative Site Groningen
Netherlands Novartis Investigative Site Harderwijk
Netherlands Novartis Investigative Site Heerlen
Netherlands Novartis Investigative Site Helmond
Netherlands Novartis Investigative Site Hengelo
Netherlands Novartis Investigative Site Rotterdam
Netherlands Novartis Investigative Site Zutphen
Peru Novartis Investigative Site Cercado De Lima Lima
Peru Novartis Investigative Site Lima
Peru Novartis Investigative Site San Borja Lima
Peru Novartis Investigative Site San Isidro Lima
Peru Novartis Investigative Site San Miguel Lima
Philippines Novartis Investigative Site Bulacan
Philippines Novartis Investigative Site Lipa City Batangas
Philippines Novartis Investigative Site Manila Metro Manila
Philippines Novartis Investigative Site Manila
Philippines Novartis Investigative Site Quezon City
Poland Novartis Investigative Site Aleksandrow Odzki
Poland Novartis Investigative Site Bielsko-Biala
Poland Novartis Investigative Site Elblag
Poland Novartis Investigative Site Inowroclaw
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Ksawerow POL
Poland Novartis Investigative Site Lodz
Poland Novartis Investigative Site Ostrow Wielkopolski
Poland Novartis Investigative Site Sopot
Poland Novartis Investigative Site Wejherowo POL
Poland Novartis Investigative Site Wroclaw
Poland Novartis Investigative Site Zawadzkie
Portugal Novartis Investigative Site Coimbra
Portugal Novartis Investigative Site Coimbra
Portugal Novartis Investigative Site Lisboa
Portugal Novartis Investigative Site Porto
Romania Novartis Investigative Site Arad
Romania Novartis Investigative Site Bacau
Romania Novartis Investigative Site Brasov
Romania Novartis Investigative Site Brasov
Romania Novartis Investigative Site Bucharest
Romania Novartis Investigative Site Bucuresti
Romania Novartis Investigative Site Cluj Napoca
Romania Novartis Investigative Site Cluj Napoca
Romania Novartis Investigative Site Cluj-Napoca
Romania Novartis Investigative Site Constanta
Romania Novartis Investigative Site Craiova ROM
Romania Novartis Investigative Site Deva ROM
Romania Novartis Investigative Site Deva
Romania Novartis Investigative Site Pitesti
Romania Novartis Investigative Site Timisoara Timis
Russian Federation Novartis Investigative Site Barnaul
Russian Federation Novartis Investigative Site Barnaul
Russian Federation Novartis Investigative Site Barnaul
Russian Federation Novartis Investigative Site Chelyabinsk
Russian Federation Novartis Investigative Site Ivanovo
Russian Federation Novartis Investigative Site Kazan
Russian Federation Novartis Investigative Site Kemerovo
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Nizhny Novgorod
Russian Federation Novartis Investigative Site Nizhny Novgorod
Russian Federation Novartis Investigative Site Novosibirsk
Russian Federation Novartis Investigative Site Novosibirsk
Russian Federation Novartis Investigative Site Omsk
Russian Federation Novartis Investigative Site Perm
Russian Federation Novartis Investigative Site Perm
Russian Federation Novartis Investigative Site Pskov
Russian Federation Novartis Investigative Site Pyatigorsk
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint-Petersburg
Russian Federation Novartis Investigative Site Saint-Petersburg
Russian Federation Novartis Investigative Site Saratov
Russian Federation Novartis Investigative Site Sestroretsk
Russian Federation Novartis Investigative Site Smolensk
Russian Federation Novartis Investigative Site Smolensk
Russian Federation Novartis Investigative Site Smolensk
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site St. Petersburg
Russian Federation Novartis Investigative Site Tomsk
Russian Federation Novartis Investigative Site Tver
Russian Federation Novartis Investigative Site Ufa
Russian Federation Novartis Investigative Site Ulyanovsk
Russian Federation Novartis Investigative Site Vladikavkaz
Russian Federation Novartis Investigative Site Volgograd
Russian Federation Novartis Investigative Site Vsevolozhsk
Russian Federation Novartis Investigative Site Yaroslavl
Russian Federation Novartis Investigative Site Yaroslavl
Slovakia Novartis Investigative Site Kezmarok
Slovakia Novartis Investigative Site Kosice
Slovakia Novartis Investigative Site Kosice Slovak Republic
Slovakia Novartis Investigative Site Kosice Slovak Republic
Slovakia Novartis Investigative Site Liptovsky Mikulas
Slovakia Novartis Investigative Site Poprad
Slovakia Novartis Investigative Site Presov
Slovakia Novartis Investigative Site Spisska Nova Ves
Slovakia Novartis Investigative Site Trencin
Slovakia Novartis Investigative Site Zilina
Slovakia Novartis Investigative Site Zvolen
South Africa Novartis Investigative Site Berea Durban
South Africa Novartis Investigative Site Cape Town
South Africa Novartis Investigative Site Cape Town
South Africa Novartis Investigative Site Durban Kwazulu Natal
South Africa Novartis Investigative Site Kempton Park ZAF
Spain Novartis Investigative Site Alzira Comunidad Valenciana
Spain Novartis Investigative Site Caceres Extremadura
Spain Novartis Investigative Site Esparraguera Barcelona
Spain Novartis Investigative Site Girona Catalunya
Spain Novartis Investigative Site La Laguna Santa Cruz De Tenerife
Spain Novartis Investigative Site Laredo Cantabria
Spain Novartis Investigative Site Leon
Spain Novartis Investigative Site Malaga Andalucia
Spain Novartis Investigative Site Marbella Andalucia
Spain Novartis Investigative Site Valencia Comunidad Valenciana
Spain Novartis Investigative Site Vila-real Castellon
Spain Novartis Investigative Site Zaragoza
Sweden Novartis Investigative Site Lidingo
Sweden Novartis Investigative Site Stockholm
Switzerland Novartis Investigative Site Gossau
Thailand Novartis Investigative Site Bangkok
Thailand Novartis Investigative Site Bangkok
Thailand Novartis Investigative Site Chiang Mai
Thailand Novartis Investigative Site Khon Kaen THA
Thailand Novartis Investigative Site Muang Nonthaburi
United Kingdom Novartis Investigative Site East Yorkshire
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site Wiltshire
Vietnam Novartis Investigative Site Hanoi
Vietnam Novartis Investigative Site Ho Chi Minh
Vietnam Novartis Investigative Site Ho Chi Minh VNM

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Argentina,  Austria,  Belgium,  Bulgaria,  Canada,  Chile,  China,  Colombia,  Croatia,  Denmark,  Estonia,  Finland,  France,  Germany,  Greece,  Hungary,  India,  Ireland,  Israel,  Italy,  Japan,  Jordan,  Latvia,  Lebanon,  Lithuania,  Mexico,  Netherlands,  Peru,  Philippines,  Poland,  Portugal,  Romania,  Russian Federation,  Slovakia,  South Africa,  Spain,  Sweden,  Switzerland,  Thailand,  United Kingdom,  Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26 Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.
The primary endpoint considered the following 2 comparison groups:
QVM149 150/50/80 µg o.d. compared with QMF149 150/160 µg o.d. both delivered via Concept1
QVM149 150/50/160 µg o.d. compared with QMF149 150/320 µg o.d. both delivered via Concept1.
26 weeks
Secondary Asthma Control Questionnaire (ACQ-7) at Week 26 and Week 52 The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means > 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means < 50% of predicted FEV1). The ACQ-7 total score reported below was calculated as the mean of scores of all 7 items and ranged between 0 and 6, with higher scores indicating worse asthma symptom control. 26 weeks, 52 weeks
Secondary Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus Salmeterol/Fluticasone at Week 26 Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.
This secondary endpoint considered the following 2 comparison groups:
QVM149 150/50/80 µg o.d. via Concept1 compared with salmeterol/fluticasone 50/500 µg b.i.d. via Accuhaler®
QVM149 150/50/160 µg o.d. via Concept 1 compared with salmeterol/fluticasone 50/500 µg b.i.d. via Accuhaler®
26 weeks
Secondary Trough FEV1 at Week 52 Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. 52 weeks
Secondary Pre-dose Forced Vital Capacity (FVC) at Week 4 and Week 12 Pre-dose FVC is defined as average of the two FVC measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FVC is the total amount of air exhaled during the FEV test. 4 weeks, 12 weeks
Secondary Trough Forced Expiratory Flow (FEF) Between 25% and 75% of FVC (FEF25-75) at 52 Weeks FEF is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Trough FEF25-75% is defined as average of the two FEF25-75% measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment. Up to Week 52
Secondary Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment PEF is a person's maximum speed of expiration. All the participants were instructed to record PEF twice daily using a mini Peak Flow Meter device, once in the morning (before taking the morning dose) and once approximately 12 h later in the evening (before taking the evening dose) at home. At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. The best of 3 values were used. Baseline, 26 weeks, 52 weeks
Secondary Change From Baseline in Percentage of Asthma Symptom-free Days Over 52 Weeks All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. Asthma symptoms free days are days with no daytime symptoms, no night-time awakenings and no symptoms on awakening. The daytime asthma symptom score was based on the daily e-diary recordings by participants with respect to shortness of breath, wheeze, cough, chest tightness, and impact on usual daily activities due to symptoms. Baseline, 52 weeks
Secondary Change From Baseline in Percentage of Days With no Daytime Symptoms Over 52 Weeks All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. For days with no daytime symptoms, all 5 evening questions must have a score = 0 with respect to shortness of breath, wheeze, cough, chest tightness and impact on usual daily activities due to symptoms, each with scores from 0 (no problems) to 4 (very severe problems). Baseline, 52 weeks
Secondary Change From Baseline in Percentage of Nights With no Night-time Awakenings Over 52 Weeks All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was "How did you sleep last night?" had to be answered with "I did not wake up because of any breathing problems" with scores from 0 (no problem)-4 (very severe problems). Baseline, 52 weeks
Secondary Change From Baseline in Percentage of Mornings With no Symptoms on Rising Over 52 Weeks All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was "How did you sleep last night?" had to be answered with "I did not wake up because of any breathing problems" with scores from 0 (no problem)-4 (very severe problems). Baseline, 52 weeks
Secondary Change From Baseline in Percentage of Days Without Rescue Medication Use Over 26 and 52 Weeks Percentage of days without rescue medication usage (100 µg salbutamol/90 µg albuterol via metered-dose inhaler) as recorded by e-diary over 26 and 52 weeks of treatment. Baseline, 26 weeks, 52 weeks
Secondary Percentage of Patients Achieving the Minimal Clinically Important Difference (MCID) ACQ = 0.5 at Week 26 and Week 52 Change from baseline in ACQ-7 scores of = 0.5 was defined as minimal clinically important difference and were considered clinically meaningful. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means > 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means < 50% of predicted FEV1). The total score was calculated as the mean of all questions. 26 weeks, 52 weeks
Secondary Time to First Hospitalization for Asthma Exacerbation Time from start of treatment until the first event (hospitalization for asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the hospitalization was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date). 52 weeks on average, up to 416 days
Secondary Time to First Asthma Exacerbation by Exacerbation Category Time from start of treatment until the first event (asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the exacerbation was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date).
The exacerbation categories were: All (mild, moderate and severe), combination of moderate or severe and severe.
52 weeks on average, up to 416 days
Secondary Annual Rate of Asthma Exacerbations by Exacerbation Category The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe. 52 weeks
Secondary Duration in Days of Asthma Exacerbations by Exacerbation Category The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe. Up to Week 52
Secondary Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe. Up to Week 52
Secondary Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbation Time from start of treatment until the first event (permanent discontinuation of study medication due to asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the date of the discontinuation of study medication was considered to calculate the time to event. 52 weeks on average, up to 416 days
Secondary Total Amount of Oral Corticosteroid Used (in Prednisone-equivalent mg Doses) to Treat Asthma Exacerbations The treatment of asthma exacerbations including the initiation of systemic corticosteroids were done according to investigator's or treating physician's medical judgement and in line with national and international recommendations. If systemic corticosteroids were required, a participant could return to the study after successfully completing a taper of approximately 7-10 days. Up to Week 52
Secondary Change From Baseline in Percentage of Rescue Medication Free Days Over 26 and 52 Weeks All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. Rescue medication free days is defined as any day where the participant did not use any puffs of rescue medication during daytime and night-time. Baseline, 26 weeks, 52 weeks
Secondary Asthma Quality of Life Questionnaire (AQLQ) at Week 52 AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). It consists of 4 domains:
Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items)
Activity limitation = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items)
Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items)
Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items)
Overall Score = Mean of Items 1 to 32 (32 items) The overall AQLQ score reported below is the mean of all 32 responses and ranges from 1 to 7, where higher scores indicate better quality of life.
52 weeks
Secondary Pre-dose FEV1 at Weeks 4 and 12 Pre-dose FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. 4 weeks, 12 weeks
Secondary Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes A composite endpoint of serious asthma outcomes is defined as asthma-related hospitalization, asthma-related intubation, or asthma-related death and was reviewed by the Adjudication Committee. Up to Week 52
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device